Search

everythinglearnresearchcommunity

for

Search:↓

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Soymetide-4 from soy can prevent hair loss caused by a cancer drug in rats.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

Ondansetron can cause serious allergic reactions, so use it carefully.

Immunoadsorption successfully treated a man's resistant polymyositis.

Chemotherapy may help with survival in children with medulloblastoma, but more research is needed.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Combining dutasteride mesotherapy with oral minoxidil is more effective for hair loss than using oral minoxidil alone.

Brentuximab may cause hair to regain color.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Researchers made new compounds that could potentially be developed into anticancer drugs.

Troglitazone increases subcutaneous fat in lipodystrophy patients.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

The data suggests that dosing differences can help manage spasticity in patients with upper motor neuron dysfunction.

New treatments like PBMC, G-CSF, and PRP show promise for helping with repeated implantation failure.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.